Market Research Report
Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets
|Published by||CBR Pharma Insights||Product code||351876|
|Published||Content info||86 Pages
|Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets|
|Published: January 1, 2016||Content info: 86 Pages||
GBI Research's latest report, "Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.
This report will allow you to -